Media ReleasesImmutep

View All Immutep News

Immutep Announces Presentations at Society for Immunotherapy of Cancer (SITC) 2018 Annual Meeting

SYDNEY, AUSTRALIA – October 2, 2018 – Immutep Limited (ASX:IMM; NASDAQ:IMMP) ("Immutep“ or “the Company“), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, today announced that clinical data on the company’s lead product candidate eftilagimod alpha (“efti” or “IMP321”), a soluble LAG-3Ig fusion protein based on the LAG-3 immune control mechanism, will be presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting being held November 7-11, 2018, in Washington, D.C.

For further information please download PDF attached:
Download this document